Treatment Options Post Exposure to COVID-19

Introductory content goes here…

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris placerat ullamcorper sem eu sodales. Praesent suscipit mauris nec augue bibendum, ut consequat massa sodales. Proin et lacus enim. Vivamus vulputate luctus ultrices. Quisque consequat porttitor fringilla. Mauris vitae nulla porttitor, gravida diam et, egestas mauris. Mauris convallis metus at urna rutrum, eget hendrerit metus porttitor. Maecenas posuere lorem rhoncus nisi eleifend mollis. 

Web Tip: This has the potential to change everything and give us freedom like that already enjoyed by those vaccinated who have a normal immune system.

CLL Society Organizes Joint Effort Urging Government Agencies to Focus on Continued COVID-19 for the Immunocompromised

In light of the FDA’s announcements regarding the discontinuation of Emergency Use Authorization for both Evusheld  and Bebtelovimab, CLL Society and eight other patient advocacy organizations sent a letter to federal officials requesting them to immediately undertake thirteen specific actions that would help protect the estimated seven million Americans who are immunocompromised against COVID-19.

FDA Announces Evusheld is Not Currently Authorized for Emergency Use in the U.S.

As of 1/26/23, Evusheld (tixagevimab co-packaged with cilgavimab) is no longer available as Pre-Exposure Prophylaxis (PrEP) in the United States. That decision was made because as the virus continued to mutate, now over 90% of SARS-CoV-2 variants of concerns (VOC) circulating in the U.S. are no longer believed to be neutralized by the monoclonal antibody (mAb) cocktail.

CLL Society’s COVID-19 Update for the Week of January 23, 2023

Please read this week’s update which is pertinent to all of those who are immunocompromised, including anyone living with CLL/SLL regardless of treatment status. The goal of these weekly COVID-19 updates is to keep our community informed of the latest information available throughout the upcoming months as we approach what Dr. Brian Koffman has referred to as the potential “winter of discontent.”